Close

Morgan Stanley Sees Favorable GW Pharma (GWPH) Entry Point Ahead of Second LGS Trial Data

Go back to Morgan Stanley Sees Favorable GW Pharma (GWPH) Entry Point Ahead of Second LGS Trial Data

GW Pharma (GWPH) PT Raised to $182 at Cantor Fitzgerald Following Successful Second LGS Trial

September 26, 2016 9:48 AM EDT

Cantor Fitzgerald analyst Elemer Piros raised his price target on Buy-rated GW Pharma (NASDAQ: GWPH) to $182.00 (from $165.00) after the company reported a second successful pivotal trial in Lennox-Gastaut syndromes (LGS).

Piros commented, "The second LGS trial was in most respects a... More

GW Pharma (GWPH) Gains ~13% on Positive Epidiolex Data in LGS

September 26, 2016 7:55 AM EDT

GW Pharma (NASDAQ: GWPH) shares are trading up 12.9% after the company announced positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

... More